AAPL331.33-0.01 (0.00%) ▼|ABBV262.23-0.81 (-0.31%) ▼|ABT102.01-0.02 (-0.02%) ▼|ACN189.87-3.54 (-1.83%) ▼|ADBE250.37-7.39 (-2.87%) ▼|AMAT413.30-7.87 (-1.87%) ▼|AMD510.97+6.77 (+1.34%) ▲|AMGN375.69+0.04 (+0.01%) ▲|AMT176.46-1.26 (-0.71%) ▼|AMZN245.21-3.21 (-1.29%) ▼|AVGO338.22-1.05 (-0.31%) ▼|AXP311.49-12.94 (-3.99%) ▼|BA198.29-11.40 (-5.44%) ▼|BAC57.63-1.90 (-3.18%) ▼|BKNG170.65-0.67 (-0.39%) ▼|BLK1,026.70-31.96 (-3.02%) ▼|BMY63.23-0.51 (-0.79%) ▼|BNY152.91-1.76 (-1.14%) ▼|BRK-B518.97+2.21 (+0.43%) ▲|C132.18-4.00 (-2.93%) ▼|CAT779.62-3.92 (-0.50%) ▼|CL86.78-0.22 (-0.25%) ▼|CMCSA23.64-0.78 (-3.20%) ▼|COF201.48-5.38 (-2.60%) ▼|COP132.61-8.62 (-6.10%) ▼|COST894.03-7.32 (-0.81%) ▼|CRM249.94-5.71 (-2.23%) ▼|CSCO107.98-2.09 (-1.90%) ▼|CVS91.61-2.88 (-3.05%) ▼|CVX210.82-6.96 (-3.19%) ▼|DE668.37-15.68 (-2.29%) ▼|DHR208.23-1.13 (-0.54%) ▼|DIS106.59+0.17 (+0.16%) ▲|DUK117.52-0.26 (-0.22%) ▼|EMR145.45-1.55 (-1.05%) ▼|FDX300.53-7.74 (-2.51%) ▼|GD358.75+0.15 (+0.04%) ▲|GE312.44+5.39 (+1.75%) ▲|GEV922.10+39.29 (+4.45%) ▲|GILD147.29+0.99 (+0.67%) ▲|GM84.01-1.36 (-1.59%) ▼|GOOG339.24-2.19 (-0.64%) ▼|GOOGL342.41-2.58 (-0.75%) ▼|GS935.58-41.09 (-4.21%) ▼|HD303.26-2.22 (-0.73%) ▼|HON207.21+3.77 (+1.85%) ▲|IBM236.98-11.40 (-4.59%) ▼|INTC100.14+3.00 (+3.09%) ▲|INTU317.39-11.88 (-3.61%) ▼|ISRG381.58+4.42 (+1.17%) ▲|JNJ267.14-0.07 (-0.02%) ▼|JPM347.37-5.12 (-1.45%) ▼|KO87.88-0.83 (-0.94%) ▼|LIN460.61-2.35 (-0.51%) ▼|LLY1,132.68-3.43 (-0.30%) ▼|LMT534.70+1.24 (+0.23%) ▲|LOW193.97-0.64 (-0.33%) ▼|LRCX267.42-3.45 (-1.27%) ▼|MA567.19-6.08 (-1.06%) ▼|MCD249.70-3.09 (-1.22%) ▼|MDLZ62.44+0.34 (+0.55%) ▲|MDT92.51-1.24 (-1.32%) ▼|META673.07+2.83 (+0.42%) ▲|MMM162.12-2.55 (-1.55%) ▼|MO70.16+0.35 (+0.50%) ▲|MRK144.23+0.44 (+0.31%) ▲|MS201.50-4.78 (-2.32%) ▼|MSFT488.99-8.13 (-1.64%) ▼|MU921.89-5.72 (-0.62%) ▼|NEE80.09-0.99 (-1.22%) ▼|NFLX76.47-1.44 (-1.84%) ▼|NKE35.81-0.42 (-1.15%) ▼|NOW139.27-2.63 (-1.85%) ▼|NVDA213.67+1.50 (+0.71%) ▲|ORCL142.35+2.00 (+1.43%) ▲|PEP134.56-0.94 (-0.69%) ▼|PFE27.40-0.16 (-0.56%) ▼|PG147.28+0.61 (+0.41%) ▲|PLTR172.55-0.01 (0.00%) ▼|PM191.73-2.38 (-1.23%) ▼|QCOM185.52-2.28 (-1.21%) ▼|RTX196.74+1.24 (+0.63%) ▲|SBUX96.89+0.31 (+0.32%) ▲|SCHW105.06-2.73 (-2.53%) ▼|SO85.95+0.00 (+0.00%) ▲|SPG202.04-2.06 (-1.01%) ▼|T25.79-0.93 (-3.48%) ▼|TMO649.40+8.01 (+1.25%) ▲|TMUS173.53-6.94 (-3.85%) ▼|TSLA357.60+1.02 (+0.29%) ▲|TXN259.56-3.87 (-1.47%) ▼|UBER71.36-0.08 (-0.11%) ▼|UNH375.65-0.28 (-0.07%) ▼|UNP280.85-3.14 (-1.11%) ▼|UPS98.65-3.70 (-3.62%) ▼|USB59.62-2.61 (-4.19%) ▼|V369.95-5.68 (-1.51%) ▼|VZ49.60-1.86 (-3.61%) ▼|WFC86.95-2.77 (-3.09%) ▼|WMT107.54-0.55 (-0.51%) ▼|XOM163.34-5.98 (-3.53%) ▼|AAPL331.33-0.01 (0.00%) ▼|ABBV262.23-0.81 (-0.31%) ▼|ABT102.01-0.02 (-0.02%) ▼|ACN189.87-3.54 (-1.83%) ▼|ADBE250.37-7.39 (-2.87%) ▼|AMAT413.30-7.87 (-1.87%) ▼|AMD510.97+6.77 (+1.34%) ▲|AMGN375.69+0.04 (+0.01%) ▲|AMT176.46-1.26 (-0.71%) ▼|AMZN245.21-3.21 (-1.29%) ▼|AVGO338.22-1.05 (-0.31%) ▼|AXP311.49-12.94 (-3.99%) ▼|BA198.29-11.40 (-5.44%) ▼|BAC57.63-1.90 (-3.18%) ▼|BKNG170.65-0.67 (-0.39%) ▼|BLK1,026.70-31.96 (-3.02%) ▼|BMY63.23-0.51 (-0.79%) ▼|BNY152.91-1.76 (-1.14%) ▼|BRK-B518.97+2.21 (+0.43%) ▲|C132.18-4.00 (-2.93%) ▼|CAT779.62-3.92 (-0.50%) ▼|CL86.78-0.22 (-0.25%) ▼|CMCSA23.64-0.78 (-3.20%) ▼|COF201.48-5.38 (-2.60%) ▼|COP132.61-8.62 (-6.10%) ▼|COST894.03-7.32 (-0.81%) ▼|CRM249.94-5.71 (-2.23%) ▼|CSCO107.98-2.09 (-1.90%) ▼|CVS91.61-2.88 (-3.05%) ▼|CVX210.82-6.96 (-3.19%) ▼|DE668.37-15.68 (-2.29%) ▼|DHR208.23-1.13 (-0.54%) ▼|DIS106.59+0.17 (+0.16%) ▲|DUK117.52-0.26 (-0.22%) ▼|EMR145.45-1.55 (-1.05%) ▼|FDX300.53-7.74 (-2.51%) ▼|GD358.75+0.15 (+0.04%) ▲|GE312.44+5.39 (+1.75%) ▲|GEV922.10+39.29 (+4.45%) ▲|GILD147.29+0.99 (+0.67%) ▲|GM84.01-1.36 (-1.59%) ▼|GOOG339.24-2.19 (-0.64%) ▼|GOOGL342.41-2.58 (-0.75%) ▼|GS935.58-41.09 (-4.21%) ▼|HD303.26-2.22 (-0.73%) ▼|HON207.21+3.77 (+1.85%) ▲|IBM236.98-11.40 (-4.59%) ▼|INTC100.14+3.00 (+3.09%) ▲|INTU317.39-11.88 (-3.61%) ▼|ISRG381.58+4.42 (+1.17%) ▲|JNJ267.14-0.07 (-0.02%) ▼|JPM347.37-5.12 (-1.45%) ▼|KO87.88-0.83 (-0.94%) ▼|LIN460.61-2.35 (-0.51%) ▼|LLY1,132.68-3.43 (-0.30%) ▼|LMT534.70+1.24 (+0.23%) ▲|LOW193.97-0.64 (-0.33%) ▼|LRCX267.42-3.45 (-1.27%) ▼|MA567.19-6.08 (-1.06%) ▼|MCD249.70-3.09 (-1.22%) ▼|MDLZ62.44+0.34 (+0.55%) ▲|MDT92.51-1.24 (-1.32%) ▼|META673.07+2.83 (+0.42%) ▲|MMM162.12-2.55 (-1.55%) ▼|MO70.16+0.35 (+0.50%) ▲|MRK144.23+0.44 (+0.31%) ▲|MS201.50-4.78 (-2.32%) ▼|MSFT488.99-8.13 (-1.64%) ▼|MU921.89-5.72 (-0.62%) ▼|NEE80.09-0.99 (-1.22%) ▼|NFLX76.47-1.44 (-1.84%) ▼|NKE35.81-0.42 (-1.15%) ▼|NOW139.27-2.63 (-1.85%) ▼|NVDA213.67+1.50 (+0.71%) ▲|ORCL142.35+2.00 (+1.43%) ▲|PEP134.56-0.94 (-0.69%) ▼|PFE27.40-0.16 (-0.56%) ▼|PG147.28+0.61 (+0.41%) ▲|PLTR172.55-0.01 (0.00%) ▼|PM191.73-2.38 (-1.23%) ▼|QCOM185.52-2.28 (-1.21%) ▼|RTX196.74+1.24 (+0.63%) ▲|SBUX96.89+0.31 (+0.32%) ▲|SCHW105.06-2.73 (-2.53%) ▼|SO85.95+0.00 (+0.00%) ▲|SPG202.04-2.06 (-1.01%) ▼|T25.79-0.93 (-3.48%) ▼|TMO649.40+8.01 (+1.25%) ▲|TMUS173.53-6.94 (-3.85%) ▼|TSLA357.60+1.02 (+0.29%) ▲|TXN259.56-3.87 (-1.47%) ▼|UBER71.36-0.08 (-0.11%) ▼|UNH375.65-0.28 (-0.07%) ▼|UNP280.85-3.14 (-1.11%) ▼|UPS98.65-3.70 (-3.62%) ▼|USB59.62-2.61 (-4.19%) ▼|V369.95-5.68 (-1.51%) ▼|VZ49.60-1.86 (-3.61%) ▼|WFC86.95-2.77 (-3.09%) ▼|WMT107.54-0.55 (-0.51%) ▼|XOM163.34-5.98 (-3.53%) ▼|
25.8 C
New York
Wednesday, September 16, 2026

Tag: news

newssourceFORcompanyinformationcontent1releasesmarket

Entrata Collaborates with OpenAI to Define the Future of Autonomous Property Management

New agreement with OpenAI brings additional AI agents to rental housing at scale, transforming how properties operate and how residents experience their homes 
New agreement with OpenAI brings additional AI agents to rental housing at scale, transforming how properties operate and how residents experience their homes

VolitionRx Announces Pricing of $4.6 Million Public Offering

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7,...

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

He Predicted Gold at $5,000. Now He Says This $2 Stock Could Be Even Bigger.

A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States 
A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign

Enabled Talent launches One Company. One Talent, inviting Canadian employers to create one inclusive opportunity and build a stronger workforce.

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders

Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests.

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

CREDIT AGRICOLE S.A. ANNONCE LE REMBOURSEMENT DE SES Obligations senior non préférées remboursables émises le 3 juin 2021 pour un montant nominal total de...

CREDIT AGRICOLE S.A. ANNONCE LE REMBOURSEMENT DE SES

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNews

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers